These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29896655)

  • 1. Emergence, Diversity, and Control of New Psychoactive Substances: A Global Perspective.
    Tettey JNA; Crean C; Ifeagwu SC; Raithelhuber M
    Handb Exp Pharmacol; 2018; 252():51-67. PubMed ID: 29896655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New psychoactive substances: Are there any good options for regulating new psychoactive substances?
    Reuter P; Pardo B
    Int J Drug Policy; 2017 Feb; 40():117-122. PubMed ID: 27889115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A critical first assessment of the new pre-market approval regime for new psychoactive substances (NPS) in New Zealand.
    Wilkins C
    Addiction; 2014 Oct; 109(10):1580-6. PubMed ID: 24529166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the development of a regulated market approach to new psychoactive substances (NPS) in New Zealand using Punctuated Equilibrium Theory.
    Rychert M; Wilkins C
    Addiction; 2018 Nov; 113(11):2132-2139. PubMed ID: 29744945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scheduling of new psychoactive substance the Swiss way: A review and critical analysis.
    Grafinger KE; Bernhard W; Weinmann W
    Sci Justice; 2019 Jul; 59(4):459-466. PubMed ID: 31256819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New psychoactive substances legislation in Ireland - Perspectives from academia.
    Kavanagh PV; Power JD
    Drug Test Anal; 2014; 6(7-8):884-91. PubMed ID: 24478277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Responding to New Psychoactive Substances in the European Union: Early Warning, Risk Assessment, and Control Measures.
    Evans-Brown M; Sedefov R
    Handb Exp Pharmacol; 2018; 252():3-49. PubMed ID: 30194542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory approaches to new psychoactive substances (NPS) in the European Union.
    Hughes B; Griffiths P
    Addiction; 2014 Oct; 109(10):1591-3. PubMed ID: 25163707
    [No Abstract]   [Full Text] [Related]  

  • 9. Prevalence of new psychoactive substances in Northeast Asia from 2007 to 2015.
    Lee J; Yang S; Kang Y; Han E; Feng LY; Li JH; Chung H
    Forensic Sci Int; 2017 Mar; 272():1-9. PubMed ID: 28088088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the 'added value' of European policy on new psychoactive substances.
    Chatwin C
    Int J Drug Policy; 2017 Feb; 40():111-116. PubMed ID: 27956185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding and managing the new psychoactive substances phenomenon: a holistic approach.
    Zamengo L; Frison G; Zwitser G
    J Public Health Policy; 2019 Jun; 40(2):217-235. PubMed ID: 30504846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicology in international drug control-Prioritizing the most harmful, persistent and prevalent substances.
    Ifeagwu SC; Raithelhuber M; Crean C; Gerostamoulos D; Chung H; Tettey JN
    Forensic Sci Int; 2017 May; 274():2-6. PubMed ID: 27899215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prohibition is a key driver of the new psychoactive substances (NPS) phenomenon.
    Rolles S; Kushlick D
    Addiction; 2014 Oct; 109(10):1589-90. PubMed ID: 25163705
    [No Abstract]   [Full Text] [Related]  

  • 14. A critical examination of the definition of 'psychoactive effect' in Australian drug legislation.
    Barratt MJ; Seear K; Lancaster K
    Int J Drug Policy; 2017 Feb; 40():16-25. PubMed ID: 27884504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Taking the cat-and-mouse game to the next level: different perspectives on the introduction of the German New Psychoactive Substances Act.
    Kühnl R; Aydin D; Horn S; Olderbak S; Verthein U; Kraus L
    Harm Reduct J; 2022 Nov; 19(1):122. PubMed ID: 36329471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The interim regulated legal market for NPS ('legal high') products in New Zealand: The impact of new retail restrictions and product licensing.
    Wilkins C
    Drug Test Anal; 2014; 6(7-8):868-75. PubMed ID: 24817124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New psychoactive substances (NPS) on cryptomarket fora: An exploratory study of characteristics of forum activity between NPS buyers and vendors.
    Van Hout MC; Hearne E
    Int J Drug Policy; 2017 Feb; 40():102-110. PubMed ID: 28027812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The challenge of a ban on animal testing for the development of a regulated legal market for new psychoactive substances (NPS) ('legal highs') in New Zealand: Issues and options for resolution.
    Rychert M; Wilkins C
    Int J Drug Policy; 2015 Dec; 26(12):1273-8. PubMed ID: 26364077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New psychoactive substances: catalysing a shift in forensic science practice?
    Tettey J; Crean C
    Philos Trans R Soc Lond B Biol Sci; 2015 Aug; 370(1674):. PubMed ID: 26101290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of legislative management for new psychoactive substances control among Taiwan, South Korea, and Japan.
    Feng LY; Wada K; Chung H; Han E; Li JH
    Kaohsiung J Med Sci; 2020 Feb; 36(2):135-142. PubMed ID: 31643137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.